MEL-JUSO Belvarafenib 50mg QD Cobi 20mg QOD	MEL-JUSO Belvarafenib 100mg BID Cobi 20mg QOD	MEL-JUSO Belvarafenib 200mg BID Cobi 20mg QOD	MEL-JUSO Belvarafenib 400mg BID Cobi 20mg QOD	MEL-JUSO Belvarafenib 50mg QD Cobi 20mg QD	MEL–JUSO Belvarafenib 100mg BID Cobi 20mg QD	MEL-JUSO Belvarafenib 200mg BID Cobi 20mg QD	MEL-JUSO Belvarafenib 400mg BID Cobi 20mg QD	MEL-JUSO Belvarafenib 50mg QD Cobi 40mg QD	MEL-JUSO Belvarafenib 100mg BID Cobi 40mg QD		MEL-JUSO Belvarafenib 200mg BID Cobi 40mg QD	MEL-JUSO Belvarafenib 400mg BID Cobi 40mg QD		MEL-JUSO Belvarafenib 50mg QD Cobi 60mg QD	MEL-JUSO Belvarafenib 100mg BID Cobi 60mg QD		MEL-JUSO Belvarafenib 200mg BID Cobi 60mg QD	MEL-JUSO Belvarafenib 400mg BID Cobi 60mg QD	
RelativeViability  -2  1.00  -75  -0.50  -25  0.00	WElativeViability  RelativeViability  7-2  1.00  0.75  0.50  0.25  0.00  -3	Relative Viability  1.00  0.75  0.50  0.25  0.00  -3 -	RelativeViability  1.00  0.75  0.50  0.25  0.00  -3	RelativeViability  1.00 0.75 0.50 0.25 0.00	Mexi_Copimetinib of the control of t	RelativeViability  1.00  0.75  0.50  0.25  0.00  -3 -	Relative Viability  1.00  0.75  0.50  0.25  0.00  -3 -	RelativeViability  1.00  0.75  0.50  0.25  0.00  -3	Relative Viability  1.00  O.75  O.50  O.25  O.00  -3 -	Relative Viability  1.00  0.75  0.50  0.25  0.00  -3	Relative	veViability  1.00	Relative Viability		delative Viability  1.00  0.75  0.50  0.25  0.00  -3	RelativeViability  1.00 Wn -2 - 0.75 itself (00 O)    WE WI -2 - 0.50 O)    0.25 O)    0.25 O)    -3 -	B	RelativeViability  1.00  Nn -2 -  0.75  0.50  0.25  0.00  -3 -	RelativeViability  1.00  0.75  0.50  0.25  0.00
-4 -3 -2 panRAFi_Belvarafenib uM  MEL-JUSO Belvarafenib 50mg QD Cobi 20mg QOD	-4 -3 -2 panRAFi_Belvarafenib uM  MEL-JUSO Belvarafenib 100mg BID Cobi 20mg QOD	-4 -3 -2 panRAFi_Belvarafenib uM  MEL-JUSO Belvarafenib 200mg BID Cobi 20mg QOD	-4 -3 -2 panRAFi_Belvarafenib uM  MEL-JUSO Belvarafenib 400mg BID Cobi 20mg QOD	panRAFi_Belvarafenib uM  MEL-JUSO Belvarafenib 50mg QD Cobi 20mg QD	-4 -3 -2 panRAFi_Belvarafenib uM  MEL-JUSO Belvarafenib 100mg BID Cobi 20mg QD	-4 -3 -2 panRAFi_Belvarafenib uM  MEL-JUSO Belvarafenib 200mg BID Cobi 20mg QD	-4 -3 -2 panRAFi_Belvarafenib uM  MEL-JUSO Belvarafenib 400mg BID Cobi 20mg QD	-4 -3 -2 panRAFi_Belvarafenib uM  MEL-JUSO Belvarafenib 50mg QD Cobi 40mg QD	-4 -3 panRAFi_Belvarafenib uM  MEL-JUSO Belvarafenib 100mg BIE Cobi 40mg QD		-4 -3 -2 panRAFi_Belvarafenib uM  MEL-JUSO Belvarafenib 200mg BID Cobi 40mg QD	-4 -3 -2 panRAFi_Belvarafenib uM  MEL-JUSO Belvarafenib 400mg BID Cobi 40mg QD		panRAFi_Belvarafenib uM  MEL-JUSO Belvarafenib 50mg QD Cobi 60mg QD	-4 -3 -2 panRAFi_Belvarafenib uM  MEL-JUSO Belvarafenib 100mg BID Cobi 60mg QD		-4 -3 -2 panRAFi_Belvarafenib uM  MEL-JUSO Belvarafenib 200mg BID Cobi 60mg QD	-4 -3 panRAFi_Belvarafenib uM  MEL-JUSO Belvarafenib 400mg BID Cobi 60mg QD	-2
HSA Excess 1.0 0.5 0.5 0.0 -0.5 -1.0	HSA Excess Who dispute the control of the control o	HSA Excess 1.0 0.0 -0.5 -0.5 -1.0 -3	HSA Excess  1.0  0.0  -0.5  -1.0  -3 -	HSA Excess 1.0 0.5 0.0 -0.5 -1.0	MEKi_Copimetinib uM	HSA Excess 1.0 0.0 -0.5 -0.5 -1.0 -3	HSA Excess 1.0 0.0 0.0 1.0 1.0 0.0 1.0 0.0 0.0 0.0	HSA Excess 1.0 0.0 0.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0	HSA Excess  1.0  0.0  0.0  0.0  -0.5  WHELL REPORT OF THE PROOF TH	HSA Excess  1.0  0.0  -0.5  -0.5  -1.0  -3	HSA SA SA SA SA SA SA SA SA SA	-1- SA Excess 1.0 White of the property of the	HSA Excess 1.0 0.0 0.0 0.0 -0.5 -0.5 -1.0 -3 -		HSA Excess 1.0 0.0 -0.5 -0.5 -1.0 -3	HSA Excess 1.0 0.5 0.0 0.0 Vin qiritingingingingingingingingingingingingingi		HSA Excess  1.0  0.0  -0.5  -1.0  -3	HSA Excess 1.0 0.5 0.0 -0.5 -1.0
-4 -3 -2 panRAFi_Belvarafenib uM  MEL-JUSO Belvarafenib 50mg QD Cobi 20mg QOD	-4 -3 -2 panRAFi_Belvarafenib uM  MEL-JUSO Belvarafenib 100mg BID Cobi 20mg QOD	-4 -3 -2 panRAFi_Belvarafenib uM  MEL-JUSO Belvarafenib 200mg BID Cobi 20mg QOD	panRAFi_Belvarafenib uM  MEL-JUSO Belvarafenib 400mg BID Cobi 20mg QOD	-4 -3 -2 panRAFi_Belvarafenib uM  MEL-JUSO Belvarafenib 50mg QD Cobi 20mg QD	-4 -3 -2 panRAFi_Belvarafenib uM  MEL-JUSO Belvarafenib 100mg BID Cobi 20mg QD	panRAFi_Belvarafenib uM  MEL-JUSO Belvarafenib 200mg BID Cobi 20mg QD	-4 -3 -2 panRAFi_Belvarafenib uM  MEL-JUSO Belvarafenib 400mg BID Cobi 20mg QD	panRAFi_Belvarafenib uM  MEL-JUSO Belvarafenib 50mg QD Cobi 40mg QD	-4 -3 panRAFi_Belvarafenib uM  MEL-JUSO Belvarafenib 100mg BIE Cobi 40mg QD	-4	panRAFi_Belvarafenib uM  MEL-JUSO Belvarafenib 200mg BID Cobi 40mg QD	panRAFi_Belvarafenib uM  MEL-JUSO Belvarafenib 400mg BID Cobi 40mg QD	_4	panRAFi_Belvarafenib uM  MEL-JUSO Belvarafenib 50mg QD Cobi 60mg QD	-4 -3 -2 panRAFi_Belvarafenib uM  MEL-JUSO Belvarafenib 100mg BID Cobi 60mg QD		-4 -3 -2 panRAFi_Belvarafenib uM  MEL-JUSO Belvarafenib 200mg BID Cobi 60mg QD	panRAFi_Belvarafenib uM  MEL-JUSO Belvarafenib 400mg BID Cobi 60mg QD	-2
MERCH TO THE PART OF THE PART	Bliss Excess 1.0 0.5 0.0 0.0 -0.5 We will provide the management of the control o	Bliss Excess 1.0 -0.5 0.0 -0.5 -1.0 -3	Bliss Excess 1.0 0.0 0.0 -0.5 -1.0 -3	Bliss Excess  1.0  0.5  0.0  -0.5  -1.0	-1 - WEK! Copiumetruip Winding Transfer of the control of the cont	Bliss Excess  1.0 0.0 0.0 1.0 -0.5 -1.0 -3 -4 -4 -3 -2	Bliss Excess 1.0 0.0 -0.5 -1.0 -3 -4 -4 -3 -2	Bliss Excess 1.0 0.5 0.0 -0.5 -1.0 -3 -3 -4 -4 -3 -3 -2	Bliss Excess  1.0 0.0 0.0 -0.5 -1.0 -3 -4 -4 -3	Bliss Excess 1.0 0.0 0.0 -0.5 -1.0 -3	Bliss -4 -3 -2	SS Excess 1.0 0.0 0.0 -0.5 -1.0 -3 -4 -3 -2	Bliss Excess 1.0 0.0 0.0 -0.5 -0.5 -1.0 -3		Bliss Excess 1.0 0.0 0.0 -0.5 -1.0 -3 -4 -4 -3 -2	Bliss Excess  1.0  0.5  0.0  -0.5  -1.0  -3 -	-4 -3 -2	Bliss Excess 1.0 0.0 -0.5 -1.0 -3	Bliss Excess 1.0 0.5 0.0 -0.5 -1.0
SK-MEL-2 Belvarafenib 50mg QD Cobi 20mg QOD	SK-MEL-2 Belvarafenib 100mg BID Cobi 20mg QOD	SK-MEL-2 Belvarafenib 200mg BID Cobi 20mg QOD	SK-MEL-2 Belvarafenib 400mg BID Cobi 20mg QOD	SK-MEL-2 Belvarafenib 50mg QD Cobi 20mg QD	SK-MEL-2 Belvarafenib 100mg BID Cobi 20mg QD	SK-MEL-2 Belvarafenib 200mg BID Cobi 20mg QD	SK-MEL-2 Belvarafenib 400mg BID Cobi 20mg QD	SK-MEL-2 Belvarafenib 50mg QD Cobi 40mg QD	SK-MEL-2 Belvarafenib 100mg BID Cobi 40mg QD		SK-MEL-2 Belvarafenib 200mg BID Cobi 40mg QD	SK-MEL-2 Belvarafenib 400mg BID Cobi 40mg QD		SK-MEL-2 Belvarafenib 50mg QD Cobi 60mg QD	SK-MEL-2 Belvarafenib 100mg BID Cobi 60mg QD		SK-MEL-2 Belvarafenib 200mg BID Cobi 60mg QD	SK-MEL-2 Belvarafenib 400mg BID Cobi 60mg QD	
Relative Viability  0.9  0.6  0.3  0.0	Who administration of the control of	Relative Viability  O.9  O.6  O.3  O.0  -3	Relative Viability  Winding in the control of the c	Relative Viability  0.9  0.6  0.3  0.0	MEK! Cobimetinib uM	Relative Viability  0.9  0.6  0.3  0.0  -3	Relative Viability  0.9 0.6 0.3 0.0 -3	RelativeViability  Who dimeting the property of the property o	RelativeViability  0.9  0.6  0.3  0.0  -3	Relative Viability  Win qui jum qui ju	Relative	veViability  0.9  0.6  0.3  0.0  -3 -	Relative Viability  O.9  O.6  O.3  O.0  O.0  O.0  O.0  O.0  O.0  O.0	Re	delative Viability  WERE WITH THE PROPERTY OF	Relative Viability  Who can be seen as a seen	B 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	RelativeViability  O.9  O.6  O.3  O.0  -3	RelativeViability  0.9  0.6  0.3  0.0
Belvarafenib 50mg QD Cobi 20mg QOD	Belvarafenib 100mg BID Cobi 20mg QOD	Belvarafenib 200mg BID Cobi 20mg QOD	Belvarafenib 400mg BID Cobi 20mg QOD	Belvarafenib 50mg QD Cobi 20mg QD	Belvarafenib 100mg BID Cobi 20mg QD	Belvarafenib 200mg BID Cobi 20mg QD	Belvarafenib 400mg BID Cobi 20mg QD	Belvarafenib 50mg QD Cobi 40mg QD	Belvarafenib 100mg BIE Cobi 40mg QD		Belvarafenib 200mg BID Cobi 40mg QD	Belvarafenib 400mg BID Cobi 40mg QD	1	Belvarafenib 50mg QD Cobi 60mg QD	Belvarafenib 100mg BID Cobi 60mg QD	ſ	Belvarafenib 200mg BID Cobi 60mg QD	Belvarafenib 400mg BID Cobi 60mg QD	
HSA Excess 1.0 0.5 0.0 -0.5 -1.0	HSA Excess 1.0 4.0 5.5 0.0 0.0 -0.5 -0.5 -0.5 -1.0 -1.0 -3	HSA Excess  1.0  0.5  0.0  -0.5  WEK! Copiumetinib and a company of the company o	HSA Excess 1.0 0.0 0.0 0.0 1.0 1.0 1.0 1.0 1.0 1.0	HSA Excess 1.0 0.5 0.0 -0.5 -1.0	WEKi_Cobimetinib uM  -3 -	HSA Excess  1.0  0.5  0.0  -0.5  -1.0  -3	HSA Excess  1.0  0.0  0.0  1.0  1.0  1.0  1.0  1	HSA Excess 1.0 0.0 0.0 0.0 -0.5 -1.0 -3	HSA Excess 1.0 yn quijamigo 0.0 -0.5 JEM -1.0 -3 -	HSA Excess  1.0  0.0  -0.5  -0.5  -1.0  -3	HSA 3	A Excess  1.0  Nn qui jamiquo  0.0  -0.5  -0.5  -1.0  -3 -	HSA Excess  1.0  0.0  0.0  -0.5  -1.0  -3 -		HSA Excess  1.0  0.5  0.0  -0.5  -1.0  -3	HSA Excess  1.0  0.5  0.0  0.0  -0.5  -1.0  -3 -		HSA Excess  1.0  0.5  0.0  -0.5  -1.0  -3	HSA Excess 1.0 0.5 0.0 -0.5 -1.0
panRAFi_Belvarafenib uM  SK-MEL-2  Belvarafenib 50mg OD	panRAFi_Belvarafenib uM  SK-MEL-2  Belvarafenib 100mg BID	panRAFi_Belvarafenib uM  SK-MEL-2  Belvarafenib 200mg BID	panRAFi_Belvarafenib uM  SK-MEL-2  Belvarafenib 400mg BID	panRAFi_Belvarafenib uM  SK-MEL-2  Belvarafenib 50mg QD	panRAFi_Belvarafenib uM  SK-MEL-2  Belvarafenib 100mg BID	panRAFi_Belvarafenib uM  SK-MEL-2  Belvarafenib 200mg BID	panRAFi_Belvarafenib uM  SK-MEL-2  Belvarafenib 400mg BID	panRAFi_Belvarafenib uM  SK-MEL-2  Belvarafenib 50mg QD	panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 100mg BIE		panRAFi_Belvarafenib uM  SK-MEL-2 Belvarafenib 200mg BID	panRAFi_Belvarafenib uM  SK-MEL-2  Belvarafenib 400mg BID		panRAFi_Belvarafenib uM  SK-MEL-2  Belvarafenib 50mg QD	panRAFi_Belvarafenib uM  SK-MEL-2  Belvarafenib 100mg BID		panRAFi_Belvarafenib uM  SK-MEL-2  Belvarafenib 200mg BID	panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 400mg BID	
Bliss Excess 1.0 0.5 0.0 -0.5 -1.0	S Wind 20mg QOD  The state of t	Bliss Excess  -1  0.5  0.0  -0.5  -1.0  -3  -4	Bliss Excess 1.0 0.0 0.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0	Bliss Excess  1.0  0.5  0.0  -0.5  -1.0	-1 - Weki_Copimetinip ump	Bliss Excess  1.0  0.0  0.0  -0.5  -1.0  -3  -4  -4  -3  -2	Bliss Excess  1.0  0.5  0.0  -0.5  -1.0  -3  -4  -4  -3  -2	Bliss Excess  1.0  0.5  0.0  -0.5  -1.0  -3  -4  -4  -4  -3  -2	Bliss Excess  1.0  0.0  -0.5  -1.0  -3  -4  -4  -3	Bliss Excess 1.0 0.0 0.0 -0.5 -1.0 -1.0 -3	Bliss -4 -3 -2	SS Excess  1.0  0.0  -0.5  -1.0  -3  -4  -3  -2	Bliss Excess  1.0  0.0  -0.5  -0.5  -1.0  -3  -4	-3 -2	Bliss Excess 1.0 0.0 -0.5 -1.0 -3 -4 -4 -3 -3 -2	Bliss Excess  1.0  0.5  0.0  -0.5  -1.0  -3 -	-4 -3 -2	Bliss Excess  1.0  0.0  -0.5  -1.0  -3  -4  -4  -3	Bliss Excess 1.0 0.5 0.0 -0.5 -1.0
Cobi 20mg QOD	Cobi 20mg QOD	Cobi 20mg QOD	Cobi 20mg QOD	Cobi 20mg QD	Cobi 20mg QD	Cobi 20mg QD	Cobi 20mg QD	Cobi 40mg QD	Cobi 40mg QD		Cobi 40mg QD	Cobi 40mg QD		Cobi 60mg QD	Cobi 60mg QD		Cobi 60mg QD	Cobi 60mg QD	
RelativeViability 1.00 0.75 0.50 0.25 0.00	RelativeViability  Windipeliperiod Control of the c	RelativeViability  1.00 0.75 0.50 0.25 0.00  -3 panRAFi Belvarafenib uM	Relative Viability  1.00  0.75  0.50  0.25  0.00  -3  panRAFi Belvarafenib uM	RelativeViability  1.00  0.75  0.50  0.25  0.00	The second of th	Relative Viability  1.00  0.75  0.50  0.25  0.00  -3  panRAFi Belvarafenib uM	Relative Viability  1.00 0.75 0.50 0.25 0.00  -3  panRAFi Belvarafenib uM	Relative Viability  1.00 0.75 0.50 0.25 0.00  -3  panRAFi Belvarafenib uM	RelativeViability  1.00 Win -2  0.75  0.50  0.25  0.00  -3  panRAFi Belvarafenib uM	Relative Viability  1.00  0.75  0.50  0.25  0.00  -3	Relative  -4  -3  panRAFi Belvarafenib uM	veViability 1.00 9.75 0.50 0.25 0.00  -3  panRAFi Belvarafenib uM	Relative Viability  1.00  0.75  0.50  0.25  0.00  -3 -	Page 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	Relative Viability  1.00  0.75  0.50  0.25  0.00  -3  panRAFi Belvarafenib uM	RelativeViability  1.00  0.75  0.50  0.25  0.00  -3 -	A Januarafenib uM	RelativeViability  1.00  0.75  0.50  0.25  0.00  -3  panRAFi Belvarafenib uM	RelativeViability  1.00 0.75 0.50 0.25 0.00
Cobi 20mg QOD	Cobi 20mg QOD	Cobi 20mg QOD	Cobi 20mg QOD	Cobi 20mg QD	Cobi 20mg QD	Cobi 20mg QD	Cobi 20mg QD	Cobi 40mg QD	Cobi 40mg QD	-1 -	Cobi 40mg QD	Cobi 40mg QD	-1 -	Cobi 60mg QD	Cobi 60mg QD	_1 <b>-</b> 1 -	Cobi 60mg QD	Cobi 60mg QD	
HSA Excess 1.0 0.5 0.5 0.0 -0.5 -1.0	HSA Excess  Who agriculture of the control of the c	HSA Excess  1.0  0.5  0.0  -0.5  -1.0  -3	HSA Excess  1.0  0.5  0.0  1.0  -0.5  -1.0  -3	HSA Excess 1.0 0.5 0.0 -0.5 -1.0	WEKi_Copimetinib um	HSA Excess 1.0 Wn-2- 0.5 Underling (Copy) 4 -1.0 -34 -4 -4 -4 -4 -4 -4 -4 -4 -4 -4 -4 -4	HSA Excess 1.0 0.5 0.0 0.0 -0.5 -1.0 -3	HSA Excess 1.0 0.0 0.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0	HSA Excess  1.0  0.0  0.0  -0.5  WMEK  -1.0  -3	HSA Excess  1.0  0.5  0.0  -0.5  -1.0  -3	HSA A A A A A A A A A A A A A	SA Excess  1.0  0.0  0.0  -0.5  WM -1.0  -3	HSA Excess  1.0  0.5  0.0  -0.5  -1.0  -3		HSA Excess 1.0 0.0 -0.5 -1.0 -3	HSA Excess  1.0  0.5  0.0  -0.5  -1.0  -3 -	B 3 3 4 4 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	HSA Excess 1.0 0.5 0.0 -0.5 -1.0 -3	HSA Excess 1.0 0.5 0.0 -0.5 -1.0
Bliss Excess 1.0 0.5 0.0 -0.5 -1.0	Bliss Excess  Mn quijauliqui Qo 7   Mn quija	Bliss Excess  1.0 0.0 0.0 0.0 -0.5 -1.0 -3 panRAFi_Belvarafenib uM	Bliss Excess 1.0 0.0 0.0 1.0 -0.5 -0.5 -1.0 -3 panRAFi_Belvarafenib uM	Bliss Excess 1.0 0.5 0.0 -0.5 -1.0	WEKI Copinetruip nm Para Para Para Para Para Para Para Par	Bliss Excess  1.0  0.5  0.0  0.0  1.0  1.0  1.0  1.0	Bliss Excess  1.0  0.5  0.0  -0.5  -1.0  -3  panRAFi_Belvarafenib uM	Bliss Excess 1.0 0.0 0.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0	Bliss Excess 1.0 0.5 0.5 0.0 -0.5 -1.0 -3 panRAFi_Belvarafenib uM	Bliss Excess  1.0  0.0  -0.5  -0.5  -1.0  -3  -4	Bliss  -4  -3  panRAFi_Belvarafenib uM	ass Excess 1.0 0.0 0.0 -0.5 -1.0 -3 -4 -4 -3 -3 -2 -2 -2 -3 -3 -2 -2 -3 -3 -3 -2 -3 -3 -3 -3 -3 -3 -3 -3 -3 -3 -3 -3 -3	Bliss Excess  1.0  0.0  -0.5  -0.5  -1.0  -3  -4	panRAFi_Belvarafenib uM	Bliss Excess 1.0 0.5 0.0 -0.5 -1.0 -3 panRAFi_Belvarafenib uM	Bliss Excess  1.0  0.5  0.0  0.0  -0.5  -1.0  -3 -	B B B B B B B B B B B B B B B B B B B	Bliss Excess  1.0  0.5  0.0  -0.5  -1.0  -3  panRAFi_Belvarafenib uM	Bliss Excess 1.0 0.5 0.0 -0.5 -1.0